|
| 沃诺拉赞富马酸盐与传统质子泵抑制药临床疗效对比研究进展 |
| Research Progress on the Comparison of the Clinical Effect Between Vonoprazan Fumarate and Traditional Potassium competitive Acid Blocker |
| |
| DOI： |
| 中文关键词: 沃诺拉赞富马酸盐 钾离子竞争性抑酸药 胃酸相关性疾病 |
| 英文关键词:Vonoprazan pyroglutamate Potassium competitive acid blocker Acid related diseases |
| 基金项目: |
|
| 摘要点击次数: 895 |
| 全文下载次数: 1293 |
| 中文摘要: |
| 摘 要沃诺拉赞富马酸盐是一种新型的钾离子竞争性抑酸药，主要用于胃酸相关性疾病的治疗和预防，2014年在日本批准上市。与传统质子泵抑制药相比，具有众多优势，自上市后引起了广泛的关注并成为研究热点。本文从沃诺拉赞富马酸盐的临床疗效及不良反应等方面进行总结，以期为医护人员及患者提供最新信息。 |
| 英文摘要: |
| ABSTRACTVonoprazan Fumarate was an orally bioavailable potassium competitive acid blocker and approved in Japan for the treatment and prevention of acid related diseases in 2014. Compared with the traditional drugs proton pump inhibitors, TAK 438 F exhibited many advantages. So it draw wide attention rapidly become a hot worldwide topic. The review aimed to offer the latest and fastest information for Medical staff and patients by summarizing the clinical efficacy and adverse events of Vonoprazan Fumarate. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
